High-profile investor Neil Woodford isn’t the only one worried about GlaxoSmithKline’s HIV prospects. Wednesday, the British drugmaker’s shares sank as Citigroup downgraded the stock from buy to neutral and cut Glaxo earnings forecasts by up to 9%, Reuters reports. And ViiV, the company’s HIV unit, was a big reason why.
More: Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says